<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">International comparison of the German evidence-based S3guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2014-09-07">7 September 2014</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Markus</forename><surname>Moehler</surname></persName>
							<email>markus.moehler@unimedizin-mainz.de</email>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><forename type="middle">T H</forename><surname>Baltin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Matthias</forename><surname>Ebert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Fischbach</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Ines</forename><surname>Gockel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lars</forename><surname>Grenacher</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Arnulf</forename><forename type="middle">H</forename><surname>Ho ¨lscher •</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Florian</forename><surname>Lordick</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Malfertheiner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Helmut</forename><surname>Messmann</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Hans-Joachim</forename><surname>Meyer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anne</forename><surname>Palmqvist</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Ro ¨cken •</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><surname>Schuhmacher</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Stahl</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Stuschke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Vieth</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Wittekind</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dorothea</forename><surname>Wagner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><forename type="middle">P</forename><surname>Mo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">I</forename><surname>Gockel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">A</forename><surname>Palmqvist</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Medizinische</forename><surname>Klinik</surname></persName>
						</author>
						<author>
							<persName><surname>Poliklinik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">A H</forename><surname>Ho</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Á</forename><forename type="middle">S P</forename><surname>Mo</surname></persName>
						</author>
						<author>
							<persName><forename type="first">H.-J</forename><surname>Meyer</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="institution">University Medical Center Mainz</orgName>
								<address>
									<settlement>Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Johannes-Gutenberg-Universita ¨t</orgName>
								<address>
									<postCode>155101</postCode>
									<settlement>Langenbeckstraße, Mainz</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">University Hospital of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country>Germany M</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Ebert University Medical Center Mannheim</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">W. Fischbach Klinikum Aschaffenburg</orgName>
								<address>
									<settlement>Aschaffenburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="institution">Heidelberg University Hospital</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution">F. Lordick Klinikum Braunschweig</orgName>
								<address>
									<settlement>Braunschweig</settlement>
									<country>Germany P</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">Malfertheiner University Clinic Magdeburg</orgName>
								<address>
									<settlement>Magdeburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="institution">H. Messmann Klinikum Augsburg</orgName>
								<address>
									<settlement>Augsburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="institution">Sta ¨dtisches Klinikum Solingen</orgName>
								<address>
									<settlement>Solingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">C. Ro ¨cken Charite ´Universita ¨tsmedizin Berlin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country>Germany C</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="institution">Schuhmacher University Hospital Klinikum Rechts der Isar</orgName>
								<address>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<orgName type="institution">M. Stahl Kliniken Essen-Mitte</orgName>
								<address>
									<settlement>Essen</settlement>
									<country>Germany M. Stuschke</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<orgName type="institution">Essen University Hospital</orgName>
								<address>
									<settlement>Essen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff14">
								<orgName type="institution">Klinikum Bayreuth</orgName>
								<address>
									<settlement>Bayreuth</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff15">
								<orgName type="institution">Universita ¨tsmedizin Leipzig</orgName>
								<address>
									<settlement>Leipzig</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff16">
								<orgName type="institution">Center Hospitalier Universitaire Vaudois</orgName>
								<address>
									<settlement>Lausanne</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">International comparison of the German evidence-based S3guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2014-09-07">7 September 2014</date>
						</imprint>
					</monogr>
					<idno type="MD5">6DADF48C888CD309295DEBA2127FCF66</idno>
					<idno type="DOI">10.1007/s10120-014-0403-x</idno>
					<note type="submission">Received: 7 October 2013 / Accepted: 13 July 2014 / German esophagogastric cancer guideline 551</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:37+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Guidelines</term>
					<term>Esophageal cancer</term>
					<term>Gastric cancer</term>
					<term>Perioperative therapy</term>
					<term>Diagnosis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background Clinical guidelines are essential in implementing and maintaining nationwide stage-specific diagnostic and therapeutic standards.</s><s>In 2011, the first German expert consensus guideline defined the evidence for diagnosis and treatment of early and locally advanced esophagogastric cancers.</s><s>Here, we compare this guideline with other national guidelines as well as current literature.</s></p><p><s>Methods The German S3-guideline used an approved development process with de novo literature research, international guideline adaptation, or good clinical practice.</s><s>Other recent evidence-based national guidelines and current references were compared with German recommendations.</s><s>Results In the German S3 and other Western guidelines, adenocarcinomas of the esophagogastric junction (AEG) are classified according to formerly defined AEG I-III subgroups due to the high surgical impact.</s><s>To stage local disease, computed tomography of the chest and abdomen and endosonography are reinforced.</s><s>In contrast, laparoscopy is optional for staging.</s><s>Mucosal cancers (T1a) should be endoscopically resected ''en-bloc'' to allow complete histological evaluation of lateral and basal margins.</s><s>For M. Moehler and C.T.H. Baltin contributed equally.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Nationwide clinical guidelines have become more and more indispensable for the definition, implementation and maintenance of healthcare system-specific diagnostic and therapeutic standards <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref>.</s><s>These recommendations are increasingly being used in everyday clinical practice.</s><s>Despite these efforts, some published guidelines have not met high-quality methodological standards (evidence-based plus a formal consensus), being mainly based on expert consensus.</s><s>Furthermore, large randomized international studies or systematic meta-analyses increasingly define the best world-wide, evidence-based medicine strategies in multidisciplinary oncology therapy, which sometimes conflict with state healthcare system viewpoints.</s></p><p><s>Apart from many other high incidence and prevalence regions such as Japan or Portugal, more than 20,000 new diagnoses of gastric cancer, including adenocarcinoma of the lower esophagus, were made in Germany in 2008 alone <ref type="bibr" target="#b6">[7]</ref>.</s><s>Therefore, a German guideline on ''diagnosis and treatment of clinical manifestations of esophagogastric cancer'' was established in 2011, under high-quality, evidence-based data screening plus formal consensus pro-cesses (S3 process).</s><s>As other guidelines have also been updated <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>, this article compares the German recommendations within the framework of recently published studies and other well-defined national guidelines, particularly on diagnosis and treatment of early and locally advanced esophagogastric cancers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>In 2008, the German Cancer Society (DKG), the Association of Scientific Medical Societies in Germany (AWMF) and the German Cancer Aid (DKH) decided to support the development of clear evidence-based and healthcare-system-independent guidelines for all fields of oncology.</s><s>The primary aim was to develop recommendations using only methodologically established evidence-based guidelines or primary evidence, and to achieve an interdisciplinary consensus.</s><s>The first gastric cancer S3 guideline was published by the German Society of Digestion and Metabolism disease (DGVS) and can be found on the AWMF homepage (www.awmf.org)</s><s><ref type="bibr" target="#b6">[7]</ref>.</s><s>The organizing committee invited 108 experts involved in the management of gastric cancer (from 24 medical societies), patient organizations and experts in nutrition and pain.</s><s>Each medical society selected authors for ten different working groups.</s><s>The methodological support on selected key questions was provided by the Agency of Quality in Medicine (A ¨ZQ).</s><s>To identify evidence and formulate the recommendations, a specific AWMF approved development process was used.</s><s>Herein, three strategies, including de novo literature research, adaptation of other available guidelines or consensus according to good clinical practice, could be used.</s><s>After the definition of key words and inclusion/exclusion criteria, working groups conducted specific research using PubMed and the Cochrane Library.</s><s>The database of the Guidelines International Network (G-I-N) was used to search for international reference guidelines.</s><s>After establishing the evidence, all working groups discussed and approved their recommendations.</s><s>Finally, universal voting of the full consensus group (all guideline authors) took place.</s><s>When statements were difficult to draw conclusions due to limited evidence or disparate expert opinions that could not be answered by the recent guidelines <ref type="bibr">[1-3, 6, 8]</ref>, recommendations were stated as good clinical practice (GCP).</s></p><p><s>Since the diagnosis and treatment of early and locally advanced esophagogastric cancers is an evolving field, the major statements of the German S3 guideline with its grades of evidences and levels of consensus, which already included recent recommendations of Belgium <ref type="bibr" target="#b9">[10]</ref> and France <ref type="bibr" target="#b10">[11]</ref>, were now compared with recently published papers identified by PubMed (01 January 2011-1 August 2013) and other recent well-defined national guidelines out of G-I-N (NCCN GuidelinesÒ Gastric Cancer in the USA <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b8">9]</ref>, Allum et al. <ref type="bibr" target="#b7">[8]</ref> for the guideline in the UK, SIGN in Scotland <ref type="bibr">[12]</ref>).</s><s>Levels of evidence of publications were classified according to Oxford criteria <ref type="bibr" target="#b6">[7]</ref> (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Primary diagnosis and staging</head><p><s>Full endoscopy provides the highest sensitivity and specificity for the detection of neoplasia in the upper gastrointestinal tract (Table <ref type="table" target="#tab_2">2</ref>).</s><s>This is consistent across all national and international guidelines.</s><s>If cancer is suggested, a minimum of eight biopsies should be taken from all suspicious areas.</s><s>The question of how often and when the patient should undergo re-biopsy or more invasive procedures to determine histology remains unsolved (Supplemental Tables <ref type="table" target="#tab_2">1 and 2</ref>).</s><s>The NCCN and German S3 guideline made distinctions between early lesions that are potentially curative, and macroscopically large and advanced or symptomatic lesions.</s><s>For large lesions, especially symptomatic ones, in which tumors could not be detected in repeated biopsies, endoscopic resection or wrinkles using either a combined laparoscopic and endoscopic surgical procedure should be considered <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b11">[13]</ref><ref type="bibr" target="#b12">[14]</ref><ref type="bibr" target="#b13">[15]</ref>.</s><s>Additionally, there is consistency across all national guidelines that a thorough staging is mandatory for decision making, and that it has to take place before endoscopic or surgical resection or neoadjuvant treatment <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr">12]</ref> (Table <ref type="table" target="#tab_3">3</ref>).</s><s>Here, German and American experts agreed that it is still useful to base therapeutic decisions on the Siewert classification of gastroesophageal junction tumors <ref type="bibr" target="#b14">[16]</ref> (Table <ref type="table" target="#tab_4">4</ref>).</s></p><p><s>For primary staging only, B-mode ultrasonography has a sensitivity of 53-81 % and a specificity of 60-98 % for the detection of liver metastases <ref type="bibr" target="#b15">[17]</ref>.</s><s>The delineation of metastases from primary malignant and benign liver tumors is possible using contrast-enhanced B-mode ultrasonography as opposed to a computed tomography (CT) with an identical accuracy of [90 %.</s><s>B-mode ultrasonography is also at least equal to CT for the detection of cervical lymph node metastases in adenocarcinomas of the esophagogastric junction (AEG) <ref type="bibr" target="#b16">[18]</ref>.</s><s>In general, CT should be performed as contrast-enhanced examination of the thorax and abdomen and as multi-detector CT with at least a biphasic protocol (native phase and portal venous phase).</s><s>Further details are described in Supplemental Table <ref type="table" target="#tab_3">3</ref>.</s></p><p><s>The role of laparoscopy remains unclear <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr">12]</ref>.</s><s>Laparoscopy is useful in advanced-stage disease <ref type="bibr" target="#b17">[19]</ref>, and can be utilized as a last resort for patients where cancer may be suspected, despite negative biopsies and negative endoscopic ultrasonography (EUS) findings.</s><s>Furthermore, laparoscopy may be helpful for the detection or exclusion of an endoscopically uncertain linitis plastica tumor.</s></p><p><s>EUS is superior to other tomographies for imaging the esophagogastric wall layers, and is therefore the gold standard for assessing the tumor infiltration depth.</s><s>This is consistant throughout different national guidelines <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr">12]</ref>.</s><s>EUS is also the method of choice in detecting locoregional lymph node metastases, as it has equivalent sensitivity and specificity as other radiological tomographies.</s><s>However, EUS alone is not reliable enough to exclude lymph node metastases.</s><s>There is broad European consensus that EUS should be an obligatory component of staging when neoadjuvant therapy is being considered and that limitations of accuracy exist in evaluating the invasion of serosa, impassable stenosis, ulcerated tumors, undifferentiated carcinoma and increased tumor diameters <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr">[12]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Endoscopic resection</head><p><s>With regard to careful description of indication and procedure of endoscopic resection (ER), ER is considered sufficient for mucosal gastric carcinoma (T1a) in all European guidelines, as the incidence of lymph node metastatic disease is very low <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr">[12]</ref>.</s><s>Particularly, the German S3 (Supplemental Table <ref type="table" target="#tab_3">3</ref>) reiterates and enforces the focused knowledge and clear details of the Japanese guideline <ref type="bibr" target="#b18">[20]</ref>.</s><s>If the diagnostic histopathological findings confirm a submucosal carcinoma (T1b) after ER, surgical resection that includes systematic lymphadenectomy has to be performed, because database findings indicate lymph node involvement in up to 20 % of these patients.</s><s>The earlier established ''extended criteria'' for ER can only be used in the context of studies, since these need expertise, most likely present in high-volume centers <ref type="bibr" target="#b19">[21]</ref><ref type="bibr" target="#b20">[22]</ref><ref type="bibr" target="#b21">[23]</ref><ref type="bibr" target="#b22">[24]</ref>.</s><s>ER of early gastric cancer should be performed as a complete enbloc resection, which allows a complete histological evaluation of the lateral and basal margins.</s><s>Patients treated with ER should receive endoscopic surveillance with follow-up endoscopy every 3 months in the first year, every 6 months in the second year, and then annually.</s><s>For local recurrence after ER, early gastric carcinoma can be treated endoscopically, providing that there is only mucosal involvement (rT1aN0M0).</s><s>Alternatively, a surgical procedure can be selected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Surgery</head><p><s>The most relevant prognostic factors for recurrence are tumor location, the depth of local infiltration and locoregional lymph node involvement <ref type="bibr" target="#b23">[25]</ref> (Supplemental Table <ref type="table" target="#tab_4">4</ref>).</s><s>Nodal status assessment includes the preparation of all lymph nodes and the evaluation of the number of affected lymph nodes in proportion to the number examined.</s><s>The resection lines should be verified and classified (R0, R1, R2).</s><s>The primary goal of surgery is to accomplish a complete resection with negative margins (R0 resection).</s><s>This is consistent with other major guidelines on gastric cancer <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr">12]</ref>.</s><s>Furthermore, the presence of distant metastases, vascular invasion and the dissociation of tumor cells in the area of invasion are additional prognostic factors.</s><s>The dissociation of tumor cells in the area of invasion and vascular invasion have been validated as independent prognostic factors <ref type="bibr" target="#b14">[16,</ref><ref type="bibr" target="#b24">26,</ref><ref type="bibr" target="#b25">27]</ref>.</s><s>Vascular invasion is an independent prognostic factor for cardia and distal gastric cancer <ref type="bibr" target="#b14">[16,</ref><ref type="bibr" target="#b24">26]</ref>.</s></p><p><s>Proximal safety distances are based on the early works of Hermanek et al. <ref type="bibr" target="#b6">[7,</ref><ref type="bibr">12]</ref>.</s><s>Diffuse gastric carcinomas occasionally show a proximal discontinuous distribution in the gastric wall.</s><s>A proximal resection margin of 5-8 cm in situ (corresponding to [5 cm in the fresh preparation) is a safe distance, with a very low probability of tumor detection in the resection margin.</s><s>For intestinal gastric carcinomas, a discontinuous propagation was not detected.</s><s>Therefore, a sufficient distance from the proximal resection margin is 4-5 cm (2-3 cm according to the fresh preparation).</s><s>In the USA, complete resection with adequate margins of 4 cm or greater is widely considered as a standard goal (whereas the type of resection and the number of lymph node dissections remain controversial) <ref type="bibr" target="#b8">[9]</ref>.</s><s>If these proximal safety distances are maintained, only diffuse carcinomas in the lower third of the stomach can be treated with a subtotal distal gastrectomy.</s><s>For cancer in the upper third of the stomach and adenocarcinomas of the esophagogastric (AEG) junction type II and III, an expanded gastrectomy with distal esophagectomy is appropriate <ref type="bibr" target="#b6">[7,</ref><ref type="bibr">12]</ref>.</s><s>For patients with carcinoma of the intestinal type, a distal subtotal gastrectomy may be possible in cancers of the lower third and even for the middle third.</s><s>For AEG junction of the cardia and AEG type II and III, a distal esophageal resection, as well as a gastrectomy, is necessary.</s><s>For all patients with T1-T4 tumors, curative surgery should be the aim.</s><s>Patients with T4b tumors that involve non-resectable structures and those with distant metastases should not be subjected to radical surgery.</s><s>This is consistent with other major guidelines on gastric cancer <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr">12]</ref>.</s></p><p><s>There are insufficient data for cases of R1 resection where a second operation was curative.</s><s>Depending on the location of the previous R1-resection and the functional operability, a re-operation should be attempted with the aim of R0 resection.</s></p><p><s>Regional lymph nodes prevent a systemic spread of tumor cells for an uncertain length of time.</s><s>Thus, lymph node status impacts on prognosis, and is essential for the   analysis of treatment results <ref type="bibr" target="#b6">[7,</ref><ref type="bibr">12]</ref>.</s><s>For the pN status in gastric cancer, a minimum of 16 examined lymph nodes is required for a reliable assessment in Germany <ref type="bibr" target="#b6">[7]</ref>.</s><s>The UK guideline requires at least 15 examined lymph nodes <ref type="bibr" target="#b7">[8]</ref>.</s></p><p><s>Compared with D1-LAD, the majority of non-randomized studies showed a prognostic advantage, with lower morbidity and mortality for radical D2-LAD.</s><s>In the German gastric cancer study, a prognostic advantage of the D2-LAD was detected for the Union for International Cancer Control (UICC) stage II and IIIA disease <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b14">16]</ref>.</s><s>Two recent prospective observational studies confirm the results of the non-randomized studies of the 1990s <ref type="bibr" target="#b26">[28,</ref><ref type="bibr" target="#b27">29]</ref>, and randomized studies from the Netherlands and the UK confirm earlier work that found lower rates of loco-regional recurrences after D2-LAD <ref type="bibr" target="#b28">[30]</ref>.</s><s>In two randomized trials with high proportions of splenectomy/pancreatectomy, a prognostic advantage after D2-LAD could not be detected <ref type="bibr" target="#b28">[30,</ref><ref type="bibr" target="#b29">31]</ref>.</s><s>In both studies and subsequent multivariate analyses, the combined splenectomy/pancreatectomy was associated with a significant increase in morbidity and mortality, and was evaluated as an independent negative prognostic factor.</s><s>On the basis of these results, pancreatic left resection and splenectomy should be avoided.</s><s>The NCCN guidelines recommend splenectomy only when spleen or hilum is involved <ref type="bibr" target="#b8">[9]</ref>.</s><s>The 10-and 15-year results of the Dutch Gastric Cancer Study showed reduced cancer-related mortality after D2-LAD and lower loco-regional recurrence rates <ref type="bibr" target="#b30">[32]</ref><ref type="bibr" target="#b31">[33]</ref><ref type="bibr" target="#b32">[34]</ref>.</s><s>An extension of LAD, for example, para-aortic lymph node resection, does not lead to further improvement of prognosis <ref type="bibr" target="#b32">[34]</ref>.</s><s>Based on the results of two randomized trials, a D2±, D3 or D4-LAD is not recommended for gastric cancer.</s><s>Perioperative therapy</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Perioperative chemotherapy in locally advanced gastric and esophagogastric junction tumors</head><p><s>In all recent Western guidelines, there are clear recommendations for perioperative chemotherapy as a ''preferred approach'' (Scotland SIGN: GoR B [12], UK guideline: GoR: A, LoE: Ib <ref type="bibr" target="#b7">[8]</ref>, Germany S3: GoR A/B, LoE: Ib <ref type="bibr" target="#b6">[7]</ref>) for locally advanced tumors of the stomach and lower esophagus.</s><s>These recommendations are based on a detailed analysis of the literature (Tables <ref type="table" target="#tab_5">3, 4</ref>; Supplemental Table <ref type="table" target="#tab_6">5</ref>).</s><s>For the MAGIC study, hazard ratio (HR) for death was significantly lower (0.75 %) in the chemotherapy group (95 % CI 0.6-0.93,</s><s>p = 0.009) compared to surgery alone (Table <ref type="table" target="#tab_3">3</ref>).</s><s>In this trial, three ECF cycles (5-fluorouracil [5-FU], cisplatin, and epirubicin) were given before and after surgery, and there was a significant improvement in OS of 7.4 and 12.5 % after 4 and 5 years compared with surgery alone, respectively.</s><s>Data on neoadjuvant chemotherapy has been available from at least five randomized trials that included patients with lower esophageal adenocarcinoma <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b33">[35]</ref><ref type="bibr" target="#b34">[36]</ref><ref type="bibr" target="#b35">[37]</ref><ref type="bibr" target="#b36">[38]</ref><ref type="bibr" target="#b37">[39]</ref>.</s></p><p><s>In the French ACCORD trial, perioperative cisplatin/infusional 5-FU again conferred a significant benefit after 5 years on DFS (34 vs. 21 %, HR 0.68, p = 0.0033) and OS (38 vs. 24 %, HR 0.69, p = 0.021) <ref type="bibr" target="#b34">[36]</ref>.</s><s>Several metaanalyses have demonstrated a statistically significant benefit for neoadjuvant chemotherapy <ref type="bibr" target="#b38">[40]</ref><ref type="bibr" target="#b39">[41]</ref><ref type="bibr" target="#b40">[42]</ref>.</s><s>The EORTC 40954 trial, which primarily included patients with AEG junction, contributed to the evidence for neoadjuvant chemotherapy <ref type="bibr" target="#b35">[37]</ref>.</s><s>In this trial, cisplatin/5-FU as a PLF regimen was used only preoperatively.</s><s>However, the study was terminated prematurely due to lack of recruitment.</s><s>The rate of R0 resections improved significantly (81.9 vs. 66.7 %, p = 0.036), which is important because cure is impossible without R0 resection.</s><s>Furthermore, progression-free survival was significantly longer in the chemotherapy arm, with a similar median survival time in both arms.</s><s>Thus far, in many trials, the proportion of patients with tumors of the esophagus, the esophagogastric junction or the stomach in individual trials was not always clear, and results for these sites have not been reported separately (Table <ref type="table" target="#tab_3">3</ref>).</s><s>Post-hoc analysis of Medical Research Council trials showed no difference in chemotherapy effectiveness for esophageal, esophagogastric junction and distal gastric tumors <ref type="bibr" target="#b41">[43]</ref>; the above meta-analyses were limited in their value because of the inclusion of studies with mixed tumor types.</s><s>Surgical and pathological quality control was insufficient and not clearly defined <ref type="bibr" target="#b33">[35]</ref>.</s><s>The French trial had heterogeneous inclusion criteria with inclusion of patients with distal esophageal cancer <ref type="bibr" target="#b34">[36]</ref>.</s></p><p><s>In recently published trials of neoadjuvant chemotherapy for tumors of the esophagus or esophagogastric junction, patients with predominantly stage II and III disease were included <ref type="bibr" target="#b33">[35,</ref><ref type="bibr" target="#b37">39]</ref>; one study with negative results also allowed the inclusion of stage I patients <ref type="bibr" target="#b42">[44]</ref>.</s><s>Thus, results from randomized phase III trials for patients with tumors classified as uT2 N0 only have not been available.</s><s>Furthermore, the pre-therapeutic determination of nodal status is not regarded as a reliable basis for decisionmaking in general, and nodal involvement is only present in about 30-40 % of T2 tumor cases.</s><s>Also, neoadjuvant and perioperative chemotherapy have not been studied in T2 tumors without nodal involvement.</s><s>On this basis, the recommendation for neoadjuvant chemotherapy for uT2 tumors was pronounced as a ''can-recommendation'' with appropriate reluctance (GoR: 0, LoE: 1b, consensus).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neoadjuvant radiochemotherapy in uT3-4 esophagogastric junction tumors</head><p><s>As supported by nearly all Western guidelines, as shown in Table 5 <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr">12]</ref>, evidence of at least four randomized trials supported neoadjuvant radiochemotherapy (RCT) vs. resection alone in localized esophageal cancer <ref type="bibr" target="#b43">[45]</ref><ref type="bibr" target="#b44">[46]</ref><ref type="bibr" target="#b45">[47]</ref><ref type="bibr" target="#b46">[48]</ref>.</s><s>Two of these studies <ref type="bibr" target="#b43">[45,</ref><ref type="bibr" target="#b46">48]</ref> showed a statistically significant advantage (lower mortality) for neoadjuvant RCT.</s><s>One further study showed a nonsignificant trend in favor of neoadjuvant RCT.</s><s>Several previous meta-analyses <ref type="bibr" target="#b47">[49]</ref><ref type="bibr" target="#b48">[50]</ref><ref type="bibr" target="#b49">[51]</ref><ref type="bibr" target="#b50">[52]</ref> confirmed these results for adenocarcinoma.</s><s>The metaanalysis by Gebski demonstrated a statistically significant survival benefit for both neoadjuvant chemotherapy and neoadjuvant RCT <ref type="bibr" target="#b38">[40]</ref>.</s><s>The clinical value of preoperative radiotherapy (RT) alone versus surgery alone was also evaluated in a randomized study of 370 patients; a survival advantage of 10 % after 5 years and 7 % after 10 years (p = 0.009) was observed for RT, with no increase in perioperative mortality <ref type="bibr" target="#b51">[53]</ref>.</s></p><p><s>Preoperative RCT vs. preoperative chemotherapy alone was addressed in a recent randomized trial in locally advanced AEG <ref type="bibr" target="#b52">[54]</ref>.</s><s>When closed prematurely due to low recruitment, this trial showed a nonsignificant overall survival trend for RCT, with no significant difference in treatment-related mortality between the trial arms.</s><s>Preoperative RCT (Cross trial) also resulted in a significantly improved histological response rate, and patients with a histological tumor response had a significantly better longterm prognosis <ref type="bibr">[55]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Adjuvant strategies</head><p><s>In contrast to Asian and North American, primary adjuvant therapy concepts are not regularly standards in Europe (Tables <ref type="table" target="#tab_7">4, 5</ref>).</s><s>Despite repeated meta-analyses and positive Asian Phase III studies for chemotherapy alone (e.g., with Platin/S-1) and despite established adjuvant chemoradiation protocols for North America, no clear recommendations for adjuvant therapy solely are available in Europe <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr">12]</ref>.</s></p><p><s>Overall, survival improvement by perioperative therapy seemed to be larger than by adjuvant therapy (13 vs. 5.8 %).</s><s>The hazard ratio for OS was 0.96 (95 % CI 0.83-1.12) in ''Western'' studies, and 0.58 (95 % CI 0.44-0.76) in Asian studies.</s><s>In recent randomized trials, the results were negative in Europe, while individual studies in Asia showed a significant survival benefit for adjuvant chemotherapy.</s><s>The recently published meta-analysis by the GASTRIC Group on the basis of individual patient data with 3,838 patients from 17 studies, comprised two-thirds of all completed phase III trials with a median follow-up of more than 7 years.</s><s>This large analysis had an advantage for adjuvant chemotherapy, with an HR for OS of 0.82 (95 % CI 0.76-0.90,</s><s>p \ 0.001), corresponding to an absolute OS improvement at 5 years of 5.8 %.</s><s>This can be explained by weaker postoperative general conditions of many patients, allowing fewer feasible therapies <ref type="bibr" target="#b33">[35,</ref><ref type="bibr" target="#b34">36]</ref>.</s></p><p><s>If, however, no preoperative therapy procedures have been initiated in patients with inadequate staging or emergency surgery, adjuvant chemotherapy may be considered according to the present evidence, and offered to patients with primary locally advanced tumor stages (especially with positive LN status).</s><s>With a lack of alternative therapies for high-risk patients, the German AIO established an improved adjuvant RCTX therapy with capecitabine/oxaliplatin and irradiation <ref type="bibr" target="#b54">[56]</ref>.</s><s>Due to the expected high side effects, however, this should be considered only after extensive discussion and consideration of the side effects, compared to the aim of therapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>During recent years, significant progress has been made in the diagnostic and therapeutic measures of early and locally advanced gastric cancers, including adenocarcinoma of the lower esophagus.</s><s>In contrast to other current European guidelines, the German evidence and consensus-based S3 guideline particularly favors the eradication of H. pylori in risk populations, as well as the benefit of qualified staging procedures such as CT scans and EUS.</s><s>Although PET-CT is not considered as a routine examination for staging of gastric cancer <ref type="bibr" target="#b6">[7,</ref><ref type="bibr" target="#b8">9,</ref><ref type="bibr">12]</ref>, Italian and NCCN colleagues emphasize that-despite its drawbacks-PET/CT has a higher positive predictive value for lymph node metastasis compared to CT scan, and may have a role in monitoring response to neoadjuvant chemotherapy (NCCN: GoR; B <ref type="bibr" target="#b5">[6]</ref>; Manzoni, EUNE gastric cancer workshop in Cologne 2012).</s><s>Manzoni referred to a prospective study of 113 patients that used FDG-PET/CT, identifying occult metastatic lesions in approximately 10 % of patients with locally advanced gastric cancer.</s></p><p><s>The evidence for perioperative therapy has changed over the past years.</s><s>Since significant survival advantages were reached in recent trials, perioperative chemotherapy for locally advanced gastric tumors and the neoadjuvant radiochemotherapy for esophagogastric junction adenocarcinomas are now intensively supported in the recent European guidelines <ref type="bibr" target="#b10">[11]</ref> by high evidence levels and grade of recommendations.</s><s>In contrast to other European guidelines, the German experts acknowledged the benefit of perioperative chemotherapy for locally advanced tumors <ref type="bibr" target="#b6">[7]</ref>.</s><s>However, full consensus could not be achieved regarding a final recommendation.</s><s>At the time, when the German S3 guideline was finally completed in 2010, only the phase III MAGIC study was fully reported <ref type="bibr" target="#b33">[35]</ref>.</s><s>Important deficiencies in the study included: heterogeneous tumor locations, lack of surgical and pathological quality controls, and endoscopic staging and imprecise data on the extent of resection and the histopathological work-up.</s><s>Only 30 % of patients had pT2 tumors, and the vast majority of patients had advanced-stage, imprecisely defined tumors.</s><s>Similar data were seen in the smaller randomized ACCORD trial of 224 patients, with only 25 % being gastric carcinoma patients <ref type="bibr" target="#b34">[36]</ref>.</s><s>Deficiencies of this study were again the lack of clear surgical and pathological quality controls.</s><s>Similarly, only 50 % of patients received postoperative chemotherapy <ref type="bibr" target="#b33">[35]</ref>.</s></p><p><s>In 2009, a new clinical guideline for gastric cancer was released in the Netherlands.</s><s>In a retrospective analysis, a total of 2,511 patients with primary adenocarcinoma of the stomach were included to investigate the impact of the new guideline.</s><s>Results show that preoperative chemotherapy was given in 45 % of patients, and 25 % of resections were noncurative.</s><s>Furthermore, the resection rate was 41 % and 30-day mortality was 5.7 % <ref type="bibr" target="#b55">[57]</ref>.</s><s>Also in 2009, a similar retrospective audit was conducted in Norway, following recommendations for a perioperative chemotherapy based on National Guidelines.</s><s>In total, 336 patients were operated on for gastric cancer, and 144 (43 %) received preoperative chemotherapy.</s><s>Ninety-two (54%) of the patients started postoperative cycles and 68 (40 %) completed all cycles.</s><s>Surgical morbidity and mortality were 26 and B2 %, respectively <ref type="bibr" target="#b56">[58]</ref>.</s></p><p><s>Overall and thus far, the perioperative strategy has never been thoroughly compared with adjuvant protocols.</s><s>Currently, both strategies are also being investigated prospectively in the CRITICS trial <ref type="bibr" target="#b57">[59]</ref>.</s><s>Additionally, a comparative French multicenter study suggested a worse outcome for patients with a signet ring cell type of gastric carcinoma after perioperative chemotherapy versus surgery <ref type="bibr" target="#b58">[60]</ref>.</s><s>Therefore, the Prodice-FFCD group started a randomized controlled trial of perioperative versus adjuvant therapy in these subtype patients <ref type="bibr" target="#b59">[61]</ref>.</s><s>In esophageal cancer, a more detailed analysis of postoperative mortality of preoperative RCT showed increased mortality after RCT and resection only for patients with squamous cell carcinoma <ref type="bibr" target="#b60">[62,</ref><ref type="bibr" target="#b61">63]</ref>, whereas studies that predominantly included patients with adenocarcinoma had no increase or reduction in mortality <ref type="bibr" target="#b44">[46]</ref><ref type="bibr" target="#b45">[47]</ref><ref type="bibr" target="#b46">[48]</ref><ref type="bibr">55]</ref>.</s><s>In contrast, the metaanalysis by Fiorica showed that RCT in patients with adenocarcinoma increased post-operative mortality (HR 2.88, 95% CI 0.53-15) <ref type="bibr" target="#b47">[49]</ref>.</s><s>However, this was only observed in a study conducted in 1996 that used a form of radiotherapy that is now obsolete and also had other limitations <ref type="bibr" target="#b43">[45]</ref>.</s><s>The equivalent recommendation for chemotherapy or RCT in the preoperative phase was also justified on the basis of toxicity <ref type="bibr">[55]</ref>.</s><s>In a recent review, Crehange recommended primarily preoperative chemotherapy for patients with AEG II and III <ref type="bibr" target="#b40">[42]</ref>, whereas Renellenfitsch and colleagues clearly supported RCT in the lower esophagus in a recent meta-analysis <ref type="bibr" target="#b62">[64]</ref>.</s><s>In summary, the first German evidence-based and expert consensus guideline clearly defined molecular markers, diagnosis and staging, as well as particularly endoscopic and perioperative treatment recommendations, for locallyadvanced esophagogastric cancers.</s><s>Since new antibodies and ''small molecules'' have not yet shown any benefit for perioperative therapy, further innovative trials are needed to improve the outcome in this growing patient population.</s><s>Thus, as this guideline has been broadly developed by evidence-based medicine techniques and integrates the most recent study results in a consensus-based manner, it represents an up-to-date approach for the diagnosis,</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Key to evidence statements, grades of recommendation, and consensus</s></p></div></figDesc><table><row><cell>SIGN b</cell><cell>Level of evidence</cell><cell>Category 2A: Category 2B: Category 3: 1??: High quality 1?: Well 1-: Meta-2??: High quality systematic 2?: Well-conducted 2-: Case control or 3: Non-4: Expert</cell><cell>Based upon Based upon Based upon meta-analysis, conducted analysis, reviews of case control or case control or cohort studies analytic opinion</cell><cell>lower-level lower-level any level of systematic meta-systematic cohort studies. High quality cohort studies with with a high risk studies,</cell><cell>evidence, there evidence, evidence, there reviews of analysis, reviews of case control or cohort studies a low risk of of confoundin g e.g.,</cell><cell>is uniform there is is major NCCN randomised systematic RCTs, or with a very low risk of cofounding or bias or bias and a case</cell><cell>NCCN NCCN disagreement controlled trials reviews of RCTs with confounding or bias and a and a moderate significant risk reports,</cell><cell>consensus that consensus that that the (RCTs), or RCTs RCTs, or a high risk high probability that the probability that the that the case</cell><cell>the intervention the intervention is with a very low RCTs with a of bias relationship is causal relationship is relationship is series</cell><cell>is appropriate intervention is appropriate risk of bias low risk of causal not causal</cell><cell>appropriate bias</cell><cell>SIGN b</cell><cell>Grades of recommendation</cell><cell>A: At least one meta-analysis, systematic review of B: A body of evidence including C: A body of evidence D: Evidence level 3 GPP: Recommend ed</cell><cell>RCTs, or RCT rated as 1?? and studies rated as 2??, including studies rated or 4; or Extrapolated best practice based on the</cell><cell>directly applicable to the target population; or a directly applicable to the target as 2?, directly evidence from studies clinical experience of the</cell><cell>body of evidence consisting principally of studies population, and demonstrating overall applicable to the target rated as 2? guideline development group</cell><cell>rated as 1? , consistency of results; or population and demonstrating</cell><cell>directly applicable to the target population, and extrapolated evidence from overall consistency of</cell><cell>demonstrating overall consistency or results studies rated as 1?? or 1? results; or extrapolated</cell><cell>evidence from studies</cell><cell>rated as 2??</cell><cell>German S3 guideline d</cell><cell>Level of evidence</cell><cell>Ib: Evidence obtained IIa: Evidence obtained IIb: Evidence III: Evidence obtained IV: Evidence obtained 1a: Systematic reviews (SR) 2a: SR (with homo-3a: SR (with 4: Case-series</cell><cell>from at least one from at least one obtained from from well-designed from expert committee (with homogeneity) geneity) of cohort homogeneity) (and poor</cell><cell>randomised trial well-designed at least one other descriptive studies such reports, or opinions or of RCTs studies of case-control quality</cell><cell cols="3">controlled type of well-as comparative studies, clinical experience of 1b: Individual RCT study without designed correlative studies respected authorities (with narrow randomisation quasi-and case studies confidence interval) experiment 1c: All or none al study randomized 2b: Individual cohort study (including low quality RCT; e.g., \80 % follow-up) 2c: ''Outcomes'' studies 3b: Individual Study Case-Control cohort and case-control studies) 5: Expert opinion without controlled trials research; ecological explicit studies critical</cell><cell>appraisal,</cell><cell>or based</cell><cell>on</cell><cell>physiology,</cell><cell>bench</cell><cell>research</cell><cell>or ''first</cell><cell>principles''</cell></row><row><cell>NCCN a</cell><cell>Level of evidence</cell><cell>Category 1:</cell><cell>Based upon</cell><cell>high-level</cell><cell>evidence, there</cell><cell>is uniform</cell><cell>NCCN</cell><cell>consensus that</cell><cell>the</cell><cell>intervention is</cell><cell>appropriate</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>UK c</cell><cell>Level of evidence</cell><cell>Ia: Evidence</cell><cell>obtained from</cell><cell>meta-analysis</cell><cell>of randomised</cell><cell>controlled</cell><cell>trials (RCT)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1</head><label>1</label><figDesc></figDesc><table><row><cell>continued</cell><cell>UK c</cell><cell>Grades of recommendation</cell></row></table><note><p><s>[6]jani et al.[9], available online: http://www.jnccn.org/content/11/5/531.fullandNCCN</s><s>GuidelinesÒ Gastric Cancer V2.2013[6]available online: http://nccn.org</s><s>b SIGN [12] c Allum et al. [8] d Moehler et al. [7]</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 Staging</head><label>2</label><figDesc></figDesc><table><row><cell>German S3 guideline d</cell><cell>Patients with one or more of the following alarm</cell><cell>symptoms and with suspected esophageal or gastric</cell><cell>cancer should be referred for early endoscopy:</cell><cell>dysphagia, recurrent vomiting, anorexia, weight loss,</cell><cell>gastrointestinal bleeding. Biopsies should be</cell><cell>considered (consensus: strong)</cell><cell>Conventional B-mode ultrasound, CT thorax and CT</cell><cell>abdomen should be performed to exclude distant</cell><cell>metastasis</cell><cell>The first optional method to exclude liver metastasis</cell><cell>should be the B-mode imaging (consensus: strong).</cell><cell>The B-mode ultrasound of the neck can be used in</cell><cell>gastric cancer with clinical suspicion and should be</cell><cell>used to complement the staging of AEG tumors</cell><cell>(consensus: strong)</cell><cell>EUS is obligatory when staging patients with primary</cell><cell>tumor and the intention of curative therapy (GoR: B,</cell><cell>LoE: 2a)</cell><cell cols="2">Regarding patients with curative therapy approach, a</cell><cell>CT of the thorax and of the abdomen with intravenous</cell><cell>contrast agents and distension of the stomach with</cell><cell>water or oral contrast agents should be performed</cell><cell>(GoR: B, LoE: 2) (consensus: strong)</cell><cell>MRI should only be done in patients who have unclear</cell><cell>lesions in the CT or/and EUS that require further</cell><cell>investigations or who have had no CT because of</cell><cell>other reasons (GoR: B, LoE: 2a) (consensus: strong)</cell><cell>For patients with adenocarcinoma of the</cell><cell>esophagogastric junction who have been staged by</cell><cell>CT and EUS and have curative treatment option, a</cell><cell>PET-CT for the staging of loco-regional and non-</cell><cell>loco-regional lymph nodes and detection/exclusion of</cell><cell>other distant metastases can be considered (GoR: B,</cell><cell>LoE: 2b)</cell><cell>The PET-CT is not considered as a routine examination</cell><cell>for staging gastric cancer (consensus: strong)</cell><cell>In cases where extensive biopsies do not permit the</cell><cell>confirmation of the diagnosis despite a high suspicion</cell><cell>of carcinoma, EUS may contribute to primary</cell><cell>diagnosis (consensus: strong)</cell></row><row><cell>UK c</cell><cell>Endoscopic ultrasound is</cell><cell>recommended (GoR: B)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Initial staging with CT thorax,</cell><cell>abdomen and pelvis (GoR: B)</cell><cell></cell><cell>PET/CT in combination with</cell><cell>endoscopic ultrasound and CT</cell><cell>for assessment of esophageal</cell><cell>and EGJ-cancer (GoR: B)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>SIGN b</cell><cell>CT scan of chest and abdomen with iv contrast and</cell><cell>gastric distension (GoR: B)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Pts for any curative therapy should be staged with</cell><cell>endoscopic ultrasound ± fine needle aspiration</cell><cell>(GoR: B)</cell><cell>MRI for pts that cannot undergo CT or used for</cell><cell>additional investigation following CT/EUS (GoR: C)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Laparoscopy should be considered in pts with</cell><cell>esophageal tumors with a gastric component, and in</cell><cell>pts with gastric tumor being considered for surgery</cell><cell>where full thickness gastric wall involvement is</cell><cell cols="2">suspected (GoR: C)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Guideline NCCN a</cell><cell>Staging Endoscopy (GoR: 2A), multiple (6-8)</cell><cell>biopsies, possible EMR to evaluate</cell><cell>small lesions, possible cytologic</cell><cell>brushing if biopsies are not diagnostic</cell><cell></cell><cell></cell><cell>Endoscopic ultrasound (EUS)</cell><cell>(GoR: 2A)</cell><cell></cell><cell>CT scan is routinely used for</cell><cell>preoperative staging. Combined PET/</cell><cell>CT is better than PET scan alone</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>[6]jani et al.[9], available online: http://www.jnccn.org/content/11/5/531.fullandNCCN</s><s>GuidelinesÒ Gastric Cancer V2.2013[6]available online: http://nccn.org</s><s>b SIGN [12] c Allum et al. [8] d Moehler et al. [7]</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p><s>Comparison perioperative chemotherapy CT chemotherapy, n.s.</s><s>not significant, n.a not available, OS overall survival, EGJ esophagogastric junction</s></p></div></figDesc><table><row><cell></cell><cell cols="2">MAGIC (n = 503)</cell><cell cols="2">ACCORD (n = 224)</cell><cell>EORTC (n = 114)</cell><cell></cell></row><row><cell></cell><cell>S</cell><cell>C T? S</cell><cell>S</cell><cell>C T? S</cell><cell>S</cell><cell>C T ? S</cell></row><row><cell>R0 resection</cell><cell>66 %</cell><cell>69 %</cell><cell>74 %</cell><cell>87 %</cell><cell>67 %</cell><cell>82 %</cell></row><row><cell>p value</cell><cell>n.s.</cell><cell></cell><cell>0.04</cell><cell></cell><cell>0.036</cell><cell></cell></row><row><cell>5-y OS</cell><cell>23 %</cell><cell>36 %</cell><cell>24 %</cell><cell>38 %</cell><cell>n.a.</cell><cell>n.a.</cell></row><row><cell>Hazard ratio</cell><cell>0.75</cell><cell></cell><cell>0.69</cell><cell></cell><cell>0.84</cell><cell></cell></row><row><cell>Confidence interval</cell><cell cols="2">95 % CI 0.6-0.93</cell><cell>95 % CI 0.5-0.95</cell><cell></cell><cell>95 % CI 0.52-1.35</cell><cell></cell></row><row><cell>p value</cell><cell>0.009</cell><cell></cell><cell>0.021</cell><cell></cell><cell>0.466</cell><cell></cell></row><row><cell>Post-OP CT completed in</cell><cell cols="2">41.6 %</cell><cell>50 %</cell><cell></cell><cell>\50 %</cell><cell></cell></row><row><cell>Tumor localization</cell><cell>EGJ: 11 %</cell><cell></cell><cell cols="2">Lower esophagus and EGJ: 75%</cell><cell cols="2">EGJ and upper third of stomach: 53%</cell></row><row><cell></cell><cell cols="2">Lower esophagus: 15 %</cell><cell cols="2">Gastric cancer: 25%</cell><cell cols="2">Middle third of stomach: 26%</cell></row><row><cell></cell><cell cols="2">Gastric cancer: 74 %</cell><cell></cell><cell></cell><cell cols="2">Lower third of stomach: 21%</cell></row><row><cell>S surgery,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4</head><label>4</label><figDesc><div><p><s>Perioperative therapy</s></p></div></figDesc><table><row><cell>Guideline</cell><cell>NCCN a</cell><cell>SIGN b</cell><cell>UK c</cell><cell>German S3 guideline d</cell></row><row><cell>Preoperative</cell><cell>Preoperative CRTx is the</cell><cell></cell><cell>Definitive treatment of choice</cell><cell>In localized adenocarcinoma</cell></row><row><cell>RCTx</cell><cell>preferred approach for</cell><cell></cell><cell>for localized squamous cell</cell><cell>of the esophagogastric</cell></row><row><cell></cell><cell>localized EGJ</cell><cell></cell><cell>carcinoma of the proximal</cell><cell>junction (stage uT3 and</cell></row><row><cell></cell><cell>adenocarcinoma.</cell><cell></cell><cell>esophagus (GoR: A, LoE:</cell><cell>resectable uT4), either</cell></row><row><cell></cell><cell>Perioperative CTx is an</cell><cell></cell><cell>Ia)</cell><cell>perioperative chemotherapy</cell></row><row><cell></cell><cell>alternative but less preferred</cell><cell></cell><cell></cell><cell>or neoadjuvant RCT should</cell></row><row><cell></cell><cell>option</cell><cell></cell><cell></cell><cell>be performed. Perioperative</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>chemotherapy: (GoR: A,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>LoE: 1b). Neoadjuvant</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>RCT: (GoR: A LoE: 1a-b,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>1b-2b)</cell></row><row><cell></cell><cell>The value of preoperative</cell><cell></cell><cell>Improves long-term survival</cell><cell>Preoperative RCT should not</cell></row><row><cell></cell><cell>RCTx for pts with resectable</cell><cell></cell><cell>over surgery for esophageal</cell><cell>be performed in gastric</cell></row><row><cell></cell><cell>gastric cancer remains</cell><cell></cell><cell>adenocarcinoma (including</cell><cell>cancer</cell></row><row><cell></cell><cell>uncertain (ongoing</cell><cell></cell><cell>type I, II and III) (GoR: A,</cell><cell></cell></row><row><cell></cell><cell>international trial</cell><cell></cell><cell>LoE: Ia)</cell><cell></cell></row><row><cell></cell><cell>TOPGEAR).</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Induction CTx prior to</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>preoperative RCTx may be</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>appropriate in selected pts</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Preoperative</cell><cell>In general, Siewert I and II</cell><cell>Preoperative RTx is not</cell><cell>Not recommended for</cell><cell>In localized adenocarcinoma</cell></row><row><cell>RTx</cell><cell>tumors should be managed</cell><cell>recommended for pts with</cell><cell>esophageal squamous cell</cell><cell>of the esophagogastric</cell></row><row><cell></cell><cell>with radiation therapy</cell><cell>esophageal cancer (GoR: A)</cell><cell>carcinoma (GoR: A,</cell><cell>junction (stage uT3 and</cell></row><row><cell></cell><cell>guidelines applicable to</cell><cell></cell><cell>LoE: Ia)</cell><cell>resectable uT4), either</cell></row><row><cell></cell><cell>esophageal cancers.</cell><cell></cell><cell></cell><cell>perioperative chemotherapy</cell></row><row><cell></cell><cell>Depending on the clinical</cell><cell></cell><cell></cell><cell>or neoadjuvant RCT should</cell></row><row><cell></cell><cell>situation, Siewert III tumors,</cell><cell></cell><cell></cell><cell>be performed. Perioperative</cell></row><row><cell></cell><cell>may be more appropriately</cell><cell></cell><cell></cell><cell>chemotherapy: (GoR: A/B,</cell></row><row><cell></cell><cell>managed with radiation</cell><cell></cell><cell></cell><cell>LoE: 1b). Neoadjuvant</cell></row><row><cell></cell><cell>therapy guidelines</cell><cell></cell><cell></cell><cell>RCT: (GoR: A/B, LoE: 1a-</cell></row><row><cell></cell><cell>applicable to either</cell><cell></cell><cell></cell><cell>b, 1b-2b)</cell></row><row><cell></cell><cell>esophageal or gastric cancer.</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Dose: 45-50, 4 Gy (1.8 Gy/</cell><cell></cell><cell>Not recommended for</cell><cell></cell></row><row><cell></cell><cell>day)</cell><cell></cell><cell>esophageal adenocarcinoma</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(GoR: A, LoE: Ia)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 4 continued</head><label>4</label><figDesc></figDesc><table><row><cell>Guideline</cell><cell>NCCN a</cell><cell>SIGN b</cell><cell>UK c</cell><cell>German S3 guideline d</cell></row><row><cell>Perioperative</cell><cell>Based on results from MAGIC</cell><cell>Pts with operable esophageal</cell><cell>Preoperative CTx with</cell><cell>In localized adenocarcinoma</cell></row><row><cell>CTx</cell><cell>and FNLCC/FFCD trial:</cell><cell>cancer, who are treated</cell><cell>cisplatin and 5-FU</cell><cell>of the stomach or</cell></row><row><cell></cell><cell>category 1 recommendation</cell><cell>surgically, should be</cell><cell>improves long-term</cell><cell>esophagogastric junction</cell></row><row><cell></cell><cell>after R0 resection for all pts.</cell><cell>considered for two cycles of</cell><cell>survival over surgery alone</cell><cell>(stage uT2), preoperative</cell></row><row><cell></cell><cell>with T1b, T2 or higher, any</cell><cell>preoperative CTx with</cell><cell>for esophageal</cell><cell>chemotherapy can be</cell></row><row><cell></cell><cell>N tumor with limited lymph</cell><cell>cisplatin and 5-FU or</cell><cell>adenocarcinoma (GoR: A,</cell><cell>performed and continued</cell></row><row><cell></cell><cell>node dissection (D0 or D1).</cell><cell>offered entry into a clinical</cell><cell>LoE: Ia)</cell><cell>postoperatively (GoR: 0,</cell></row><row><cell></cell><cell>However, perioperative CTx</cell><cell>trial (GoR: B)</cell><cell></cell><cell>LoE: 1b)</cell></row><row><cell></cell><cell>is seen as an alternative to</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>RCTx</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Perioperative CTx or</cell><cell>Neoadjuvant use of either</cell><cell>Perioperative CTx conveys</cell><cell>In localized adenocarcinoma</cell></row><row><cell></cell><cell>postoperative CRTx is the</cell><cell>CTx or RTx for pts with</cell><cell>survival benefit for pts with</cell><cell>of the stomach (stage uT3</cell></row><row><cell></cell><cell>preferred approach for</cell><cell>gastric cancer is not</cell><cell>esophageal adenocarcinoma</cell><cell>and resectable uT4a),</cell></row><row><cell></cell><cell>localized gastric cancer</cell><cell>recommended outside</cell><cell>and is the preferred option</cell><cell>perioperative chemotherapy</cell></row><row><cell></cell><cell></cell><cell>clinical trials (GoR: A)</cell><cell>for type II and III EGJ-</cell><cell>should be performed, i.e. be</cell></row><row><cell></cell><cell></cell><cell></cell><cell>tumors (GoR: A; Ib)</cell><cell>started preoperatively and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>continued postoperatively</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(GoR: A/B, LoE: 1b)</cell></row><row><cell></cell><cell></cell><cell>Intraperitoneal CTx and</cell><cell>Perioperative CTx conveys a</cell><cell>In localized adenocarcinoma</cell></row><row><cell></cell><cell></cell><cell>immunotherapy for pts with</cell><cell>significant survival benefit</cell><cell>of the esophagogastric</cell></row><row><cell></cell><cell></cell><cell>gastric cancer are not</cell><cell>for pts with gastric</cell><cell>junction (stage uT3 and</cell></row><row><cell></cell><cell></cell><cell>recommended outside a</cell><cell>adenocarcinoma and is</cell><cell>resectable uT4), either</cell></row><row><cell></cell><cell></cell><cell>clinical trial (GoR: C)</cell><cell>standard of care (GoR: A,</cell><cell>perioperative chemotherapy</cell></row><row><cell></cell><cell></cell><cell></cell><cell>LoE: Ib)</cell><cell>or neoadjuvant RCT should</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>be performed. Perioperative</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>chemotherapy: (GoR: A/B,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>LoE: 1b). Neoadjuvant</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>RCT: (GoR: A/B, LoE: 1a-</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>b, 1b-2b)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Antibodies and ''small</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>molecules'' should not be</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>used for perioperative</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>therapy (consensus: strong)</cell></row></table><note><p><s><ref type="bibr" target="#b6">[7]</ref>jani et al.[9], available online: http://www.jnccn.org/content/11/5/531.fullandNCCNGuidelinesÒGastricCancer</s><s>V2.2013[6]available online: http://nccn.orgbSIGN[12]</s><s>c Allum et al.[8]d Moehler et al.[7]</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 5</head><label>5</label><figDesc><div><p><s>Postoperative therapy</s></p></div></figDesc><table><row><cell>Guideline</cell><cell>NCCN a</cell><cell>SIGN b</cell><cell>UK c</cell><cell>German S3 guideline d</cell></row><row><cell>Postoperative</cell><cell>As a result of INT-0116 trial,</cell><cell>Postoperative adjuvant</cell><cell>Improves survival for pts</cell><cell>After primary R0 resection</cell></row><row><cell>CRTx</cell><cell>postoperative RCTx is standard</cell><cell>CRTx is not recommended</cell><cell>with gastric</cell><cell>(without preoperative</cell></row><row><cell></cell><cell>of care in pts with completely</cell><cell>for pts with esophageal</cell><cell>adenocarcinoma and is</cell><cell>chemotherapy) for locally</cell></row><row><cell></cell><cell>resected gastric cancer who</cell><cell>cancer (GoR: GPP)</cell><cell>standard of care in the</cell><cell>advanced gastric cancer,</cell></row><row><cell></cell><cell>have not received preoperative</cell><cell></cell><cell>USA; it should be</cell><cell>an adjuvant chemotherapy</cell></row><row><cell></cell><cell>therapy. It is also the preferred</cell><cell></cell><cell>considered in pts at high</cell><cell>should not be performed</cell></row><row><cell></cell><cell>option after complete gastric</cell><cell></cell><cell>risk of recurrence</cell><cell>(GoR: B, LoE: 1a,</cell></row><row><cell></cell><cell>resection in T3-T4 and node-</cell><cell></cell><cell>(suboptimal debulking)</cell><cell>Consensus). Dissenting</cell></row><row><cell></cell><cell>positive T1-T2 (GoR: 1)</cell><cell></cell><cell>who have not received</cell><cell>opinion of DGHO:</cell></row><row><cell></cell><cell></cell><cell></cell><cell>neoadjuvant therapy</cell><cell>Adjuvant chemotherapy</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(GoR: A, LoE: Ib)</cell><cell>may be considered and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>offered to patients with</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>locally advanced gastric</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>cancer (especially in cases</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>with positive lymph node)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>when neoadjuvant therapy</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>has not been initiated due</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>to inadequate staging</cell></row><row><cell></cell><cell>INT-0116 Trial: only 64 % of pts</cell><cell>Postoperative CRTx for pts</cell><cell></cell><cell></cell></row><row><cell></cell><cell>completed treatment</cell><cell>with gastric cancer is not</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>recommended outside a</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>clinical trial (GoR: GPP)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>T2 N0: Observation or</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>postoperative CRTx only for pts</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>with high-risk features (poorly</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>differentiated or higher-grade</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>cancer, lamphovascular</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>invasion, neural invasion,</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>age \50 years) and R0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>resection</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>After R1 or R2: postoperative</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>CRTx is a treatment option,</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>especially for pts who have not</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>received preoperative CRTx</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Postoperative CRTx is the</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>preferred option for pts</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>undergoing less than a D2</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>lymph node dissection</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Postoperative</cell><cell>Results from ACTS GC trial and</cell><cell>Postoperative adjuvant CTx</cell><cell>Adjuvant CTx for pts with</cell><cell>In localized adenocarcinoma</cell></row><row><cell>CTx</cell><cell>CLASSIC trial support the use</cell><cell>is not recommended for</cell><cell>gastric adenocarcinoma is</cell><cell>of the stomach or</cell></row><row><cell></cell><cell>of postoperative CTx after</cell><cell>pts with esophageal cancer</cell><cell>not standard of care, but</cell><cell>esophagogastric junction</cell></row><row><cell></cell><cell>curative surgery with D2 lymph</cell><cell>(GoR: A)</cell><cell>has survival benefits in</cell><cell>(stage uT2), preoperative</cell></row><row><cell></cell><cell>node dissection in pts with</cell><cell></cell><cell>non-western populations</cell><cell>chemotherapy can be</cell></row><row><cell></cell><cell>resectable gastric cancer</cell><cell></cell><cell>and should be considered</cell><cell>performed and continued</cell></row><row><cell></cell><cell></cell><cell></cell><cell>in pts at high risk of</cell><cell>postoperatively (GoR: 0,</cell></row><row><cell></cell><cell></cell><cell></cell><cell>recurrence who have not</cell><cell>LoE: 1b)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>received neoadjuvant</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>therapy (GoR: A, LoE: Ia)</cell><cell></cell></row><row><cell></cell><cell>Postoperative CTx is offered to</cell><cell>Postoperative CTx for pts</cell><cell>Intraperitoneal CTx for pts</cell><cell>In localized adenocarcinoma</cell></row><row><cell></cell><cell>all pts with T1 or</cell><cell>with gastric cancer is not</cell><cell>with gastric</cell><cell>of the stomach (stage uT3</cell></row><row><cell></cell><cell>higher ? significantly</cell><cell>recommended outside a</cell><cell>adenocarcinoma remains</cell><cell>and resectable uT4a),</cell></row><row><cell></cell><cell>improves OS and RFS in pts</cell><cell>clinical trial (GoR: B)</cell><cell>investigational (GoR: B)</cell><cell>perioperative</cell></row><row><cell></cell><cell>with T3-T4, N0 and any T</cell><cell></cell><cell></cell><cell>chemotherapy should be</cell></row><row><cell></cell><cell>node-positive tumors</cell><cell></cell><cell></cell><cell>performed, i.e., be started</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>preoperatively and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>continued postoperatively</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(GoR: A/B, LoE: 1b)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 5 continued</head><label>5</label><figDesc></figDesc><table><row><cell>Guideline</cell><cell>NCCN a</cell><cell>SIGN b</cell><cell>UK c</cell><cell>German S3 guideline d</cell></row><row><cell></cell><cell>Effectiveness in pts with T2 N0</cell><cell></cell><cell></cell><cell>In localized adenocarcinoma</cell></row><row><cell></cell><cell>remains unclear</cell><cell></cell><cell></cell><cell>of the esophagogastric</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>junction (stage uT3 and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>resectable uT4), either</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>perioperative</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>chemotherapy or</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>neoadjuvant RCT should</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>be performed.</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Perioperative</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Chemotherapy: (GoR:</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>A/B, LoE: 1b).</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Neoadjuvant RCT: (GoR:</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>A/B, LoE: 1a-b, 1b-2b)</cell></row><row><cell></cell><cell>Postoperative CTx is an option</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>for pts with T3-T4 and node-</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>positive T1-T2 tumors after R0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>resection and a modified D2</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>lymph node dissection</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>No further treatment is necessary</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>for pts with Tis and T1, N0</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>tumors if R0 resection</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Not recommended for undergoing</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>less than a D2 lymph node</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>dissection (in this case,</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>postoperative RCTx is the</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>preferred option, GoR: 1)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Perioperative</cell><cell>B12, iron, and calcium level</cell><cell>Pts undergoing surgery for</cell><cell>Pts who are identified as</cell><cell>Nutritional support should</cell></row><row><cell>nutritional</cell><cell>should be closely monitored,</cell><cell>esophageal or gastric</cell><cell>malnourished prior to</cell><cell>be carried out regularly</cell></row><row><cell>status</cell><cell>especially for postoperative pts.</cell><cell>cancer who are identified</cell><cell>surgery should be</cell><cell>when normal food intake</cell></row><row><cell></cell><cell>Feeding jejunostomies may be</cell><cell>as being at high nutritional</cell><cell>considered for</cell><cell>in pts is insufficient to</cell></row><row><cell></cell><cell>placed if clinically indicated</cell><cell>risk should be considered</cell><cell>preoperative nutritional</cell><cell>counteract a limitation in</cell></row><row><cell></cell><cell></cell><cell>for preoperative nutritional</cell><cell>support for 10-14 days</cell><cell>prognosis due to</cell></row><row><cell></cell><cell></cell><cell>support (GoR: B)</cell><cell></cell><cell>malnutrition (consensus:</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>strong)</cell></row></table><note><p><s><ref type="bibr" target="#b6">[7]</ref>jani et al.[9], available online: http://www.jnccn.org/content/11/5/531.fullandNCCNGuidelinesÒGastricCancer</s><s>V2.2013[6]available online: http://nccn.orgbSIGN[12]</s><s>c Allum et al.[8]d Moehler et al.[7]</s></p></note></figure>
		</body>
		<back>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Esophageal and esophagogastric junction cancers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ajani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Compr Canc Netw</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="830" to="887" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</title>
		<author>
			<persName><forename type="first">A</forename><surname>Okines</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="50" to="54" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Van Cutsem</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1" to="9" />
			<date type="published" when="2010">2010. 2011</date>
		</imprint>
	</monogr>
	<note>Suppl</note>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer</title>
		<imprint>
			<date type="published" when="2011">2011</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="113" to="123" />
		</imprint>
	</monogr>
	<note>Japanese Gastric Cancer Association</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Polish Gastric Cancer Study Project; success or failure?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Popiela</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nowotwory</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="91" to="93" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<monogr>
		<title level="m" type="main">clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers V2</title>
		<author>
			<persName><surname>Nccn Guidelinesò</surname></persName>
		</author>
		<ptr target="http://nccn.org" />
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">S3-Leitlinie &apos;&apos;Magenkarzinom&apos;&apos;-Diagnostik und Therapie der Adenokarzinome des Magens und o ¨sophago-gastralen U ¨bergangs (AWMF-Regist.-Nr. 032-009-OL)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moehler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Z Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="461" to="531" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Guidelines for the management of oesophageal and gastric cancer</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Allum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1449" to="1472" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Gastric cancer, version 2.2013: featured updates to the NCCN guidelines</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ajani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Compr Canc Netw</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="531" to="546" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Een nationale praktijkrichtlijn voor de aanpak van slokdarm-en maagkanker</title>
		<author>
			<persName><forename type="first">M</forename><surname>Peeters</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Federaal Kenniscentrum voor de Gezondheidszorg (KCE)</title>
				<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="page">75</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<title level="m" type="main">Recommandations pour la pratique clinique: standards, options et recommandations 2003 pour la prise en charge des patients atteints d&apos; ade ´nocarcinomes de l&apos;estomac</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ychou</surname></persName>
		</author>
		<ptr target="http://www.sign.ac.uk/pdf/sign87.pdf" />
		<imprint>
			<date type="published" when="2004">2004. 2006</date>
		</imprint>
	</monogr>
	<note>Fe ´deration nationale des centres de lutte contre le cancer. 12. SIGN: Scottish Intercollegiate Guidelines Network. Management of oesophageal and gastric cancer</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Missed diagnoses in patients with upper gastrointestinal cancers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yalamarthi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endoscopy</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="874" to="879" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Voutilainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Juhola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Gastroenterol Hepatol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1345" to="1349" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Gastric adenocarcinoma missed at endoscopy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Amin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J R Coll Surg Edinb</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="681" to="684" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Siewert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">228</biblScope>
			<biblScope unit="page" from="449" to="461" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Baseline and contrast-enhanced ultrasound of the liver in tumor patients</title>
		<author>
			<persName><forename type="first">A</forename><surname>Oldenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Albrecht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ultraschall Med</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="488" to="498" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Van Vliet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="200" to="206" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Power</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Surg</title>
		<imprint>
			<biblScope unit="volume">208</biblScope>
			<biblScope unit="page" from="173" to="178" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Aiko</forename><forename type="middle">T</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="97" to="100" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract</title>
		<author>
			<persName><forename type="first">R</forename><surname>Soetikno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="4490" to="4498" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Clinical validity of endoscopic submucosal dissection for submucosal invasive gastric cancer: a single-center study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sanomura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="97" to="105" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Trends in characteristics of surgically treated early gastric cancer patients after the introduction of gastric cancer treatment guidelines in Japan</title>
		<author>
			<persName><forename type="first">N</forename><surname>Tanaka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="74" to="77" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Lymph node metastasis from undifferentiatedtype mucosal gastric cancer satisfying the expanded criteria for endoscopic resection based on routine histological examination</title>
		<author>
			<persName><forename type="first">T</forename><surname>Hirasawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="267" to="270" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lorenzen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2119" to="2127" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Multivariate prognostic study on large gastric cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Shiraishi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="14" to="18" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Recent advances in conventional and molecular prognostic factors for gastric carcinoma</title>
		<author>
			<persName><forename type="first">D</forename><surname>Nitti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Surg Oncol Clin N Am</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="467" to="483" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Prospective comparison of D1 vs modified D2 gastrectomy for carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Edwards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="1888" to="1892" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Degiuli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="1727" to="1732" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Extended lymph-node dissection for gastric cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Bonenkamp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="908" to="914" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cuschieri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1522" to="1530" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hartgrink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2069" to="2077" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Status of extended lymph node dissection: locoregional control is the only way to survive gastric cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hartgrink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Van De Velde</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="153" to="165" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial</title>
		<author>
			<persName><forename type="first">I</forename><surname>Songun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="439" to="449" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="11" to="20" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus</title>
		<author>
			<persName><forename type="first">V</forename><surname>Boige</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page">18S</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954</title>
		<author>
			<persName><forename type="first">C</forename><surname>Schuhmacher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">35</biblScope>
			<biblScope unit="page" from="5210" to="5218" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kelsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="3719" to="3725" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer</title>
		<author>
			<persName><forename type="first">W</forename><surname>Allum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="5062" to="5067" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a metaanalysis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Gebski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="226" to="234" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Urschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blewett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="274" to="278" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Resectable adenocarcinoma of the oesophagogastric junction care: which perioperative treatment? Cancer Radiother</title>
		<author>
			<persName><forename type="first">G</forename><surname>Crehange</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="365" to="373" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Okines</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1529" to="1534" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kelsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="1979" to="1984" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">A comparison of multimodal therapy and surgery for esophageal adenocarcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Walsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">335</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="462" to="467" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Urba</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="305" to="313" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Burmeister</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="656" to="668" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tepper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1086" to="1092" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<monogr>
		<title level="m" type="main">Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis Gut</title>
		<author>
			<persName><forename type="first">F</forename><surname>Fiorica</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2004">2004</date>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="925" to="930" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response</title>
		<author>
			<persName><forename type="first">J</forename><surname>Geh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Radiother Oncol</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="236" to="244" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Malthaner</surname></persName>
		</author>
		<ptr target="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529457/pdf/1741-7015-2-35.pdf" />
	</analytic>
	<monogr>
		<title level="j">BMC Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="issue">35</biblScope>
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Urschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vasan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg</title>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="538" to="543" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-report on 370 patients</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="929" to="934" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stahl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="851" to="856" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Preoperative chemoradiotherapy for esophageal or junctional cancer</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hagen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2074" to="2084" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Oxaliplatin and capecitabine-based chemoradiotherapy for gastric cancer-an extended phase I MARGIT and AIO trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Hofheinz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Radiat Oncol Biol Phys</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="142" to="147" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Adherence to national guidelines for gastric cancer in the Netherlands: a retrospective population-based audit</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Damhuis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Hartgrink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cancer</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1156" to="1161" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: a retrospective audit</title>
		<author>
			<persName><forename type="first">T</forename><surname>Holmebakk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Frykholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Viste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Surg Oncol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="610" to="616" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Dikken</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">329</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Messager</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Surg</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="684" to="693" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>discussion 693</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas-PRODIGE 19-FFCD1103-ADCI002</title>
		<author>
			<persName><forename type="first">G</forename><surname>Piessen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">281</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bosset</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">337</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="161" to="167" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nygaard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">World J Surg</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1104" to="1109" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus</title>
		<author>
			<persName><forename type="first">U</forename><surname>Ronellenfitsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">8107</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
